Skip to main content
SpringerLink
Log in

Fondaparinux sodium is associated with less major bleeding than enoxaparin sodium, regardless of the duration of therapy

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. Jolly S, Mehta SR, Wallentin L, Afzal R, Budaj A, Fox KAA, Col J, Rupprecht HJ, Granger CB, Yusuf S.The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial. ESC Congress 2007: Annual Congress of the European Society of Cardiology: 187 (plus oral presentation) abstr. P1265, Sep 2007

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fondaparinux sodium is associated with less major bleeding than enoxaparin sodium, regardless of the duration of therapy. React. Wkly. 1169, 5 (2007). https://doi.org/10.2165/00128415-200711690-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711690-00009

Keywords

Search

Navigation